HawkScreener
Register Sign In
Dashboard Screener Heatmap Compare Sign In

MXCT

MaxCyte, Inc. (NASDAQ)

Healthcare — Medical Devices

MaxCyte, Inc., a life sciences company, discovers, develops, and commercializes cell therapeutics in the United States and internationally. The company's products consists of ExPERT ATx, a static electroporation instrument for small to medium scale transfection; ExPERT STx, a flow electroporation for protein production and drug development, as well as expression of therapeutic targets for cell-based assays; ExPERT GTx, a flow electroporation for large scale transfection in therapeutic applications; and ExPERT VLx for very large volume cell-engineering. It also provides disposable processing assemblies (PAs) to process and electroporate cells; and accessories supporting PAs, such as electroporation buffer solution and software protocols. The company licenses and sells its instruments and technology; and sells its consumables to developers of cell therapies, as well as to pharmaceutical and biotechnology companies for use in drug discovery and development, and bio-manufacturing. The company has strategic partnership with VectorBuilder focused on co-developing a new gene delivery solution. MaxCyte, Inc. was incorporated in 1998 and is headquartered in Rockville, Maryland.

None 4 analysts
$1.23
(0.00%)
Target: $4.11 (233.9%)
Sign in to add MXCT to a watchlist or set price alerts.

Price History

52-Week Range

Fundamentals

Market Cap$131.76M
P/E Ratio (TTM)-
Forward P/E-4.94
EPS (TTM)$-0.36
Dividend Yield-
Profit Margin-121.16%
Revenue Growth-7.10%
ROE-21.30%
Debt/Equity10.42
Recommendation None
Analyst Target$4.11
Analysts4
Indexes NASDAQ

Technical Indicators

RSI (14)60.3
Beta1.67
SMA 20-
SMA 40-
52-Week High$2.37
52-Week Low$0.64
50-Day Avg$1.05
200-Day Avg$1.20
Avg Volume$1.15M
Volume482.4K

Performance Analysis

NEUTRAL

MXCT presents a mixed picture with both positive and negative indicators.

~ Trading at 34% of its 52-week range.
+ RSI at 60.3 shows positive momentum.
+ Price is above both the 50-day and 200-day moving averages — strong uptrend.
- Revenue declined 7.1% year-over-year.
- Operating at a loss with -121.2% margin.
~ Wall Street consensus is "none" from 4 analysts.
+ Average analyst target of $4.11 implies 233.9% upside.

Recent News

Loading news...
Sign in for full analysis Unlock insider trading data, options chain, news feed, and more.
Sign In

Last updated: Jul 02, 2026 13:21 UTC

Back to Screener Export Report